Innate Pharma Files 6-K Report with Press Release
Ticker: IPHYF · Form: 6-K · Filed: Mar 25, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K filing on March 25th, including a press release. Check it for updates.
AI Summary
On March 25, 2025, Innate Pharma SA filed a Form 6-K report. This filing includes a press release dated March 25, 2025, as Exhibit 99.1. The company is a foreign private issuer and files its annual reports under Form 20-F.
Why It Matters
This filing provides an update from Innate Pharma SA, potentially containing material information for investors regarding the company's operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a press release, with no immediate indication of significant financial or operational changes.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- March 25, 2025 (date) — Filing and Press Release Date
- 001-39084 (other) — Commission File Number
- Form 20-F (other) — Annual Report Form
- Exhibit 99.1 (other) — Press Release Exhibit
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that Innate Pharma SA is required to disclose to the public in France, including a press release dated March 25, 2025.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
What type of annual report does Innate Pharma SA file?
Innate Pharma SA files its annual reports under cover of Form 20-F.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release dated March 25, 2025, is included in this filing.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 25, 2025 regarding Innate Pharma SA (IPHYF).